Nektar Therapeutics Price Target Cut to $14.00 (NKTR)
Research analysts at JPMorgan Chase & Co. reduced their price target on shares of Nektar Therapeutics (NASDAQ:NKTR) from $15.00 to $14.00 in a report released on Monday, American Banking & Market News reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price objective points to a potential upside of 34.04% from the stock’s previous close.
NKTR has been the subject of a number of other recent research reports. Analysts at Cowen and Company reiterated a “buy” rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research note to investors on Friday. They now have a $17.00 price target on the stock. Separately, analysts at Brean Capital reiterated a “buy” rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research note to investors on Friday. They now have a $14.00 price target on the stock, down previously from $17.00. Finally, analysts at William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research note to investors on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $13.71.
Shares of Nektar Therapeutics (NASDAQ:NKTR) traded down 0.91% during mid-day trading on Monday, hitting $10.445. The stock had a trading volume of 3,328,014 shares. Nektar Therapeutics has a one year low of $5.65 and a one year high of $14.47. The stock’s 50-day moving average is $12.57 and its 200-day moving average is $11.21. The company’s market cap is $1.209 billion. Nektar Therapeutics also was the target of unusually large options trading on Friday. Stock investors bought 16,582 call options on the stock. This is an increase of approximately 588% compared to the average daily volume of 2,409 call options.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.07. The company had revenue of $33.86 million for the quarter, compared to the consensus estimate of $26.22 million. The company’s quarterly revenue was up 43.0% on a year-over-year basis. Analysts expect that Nektar Therapeutics will post $-1.09 EPS for the current fiscal year.
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.